Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis

被引:12
作者
Akcali, Cenk [1 ]
Guven, Ebru Homurlu [2 ]
Kirtak, Necmettin [1 ]
Inaloz, H. Serhat [1 ]
Ozgoztasi, Orhan [1 ]
Guvenc, Ulas [3 ]
机构
[1] Gaziantep Univ, Fac Med, Dept Dermatol, TR-27070 Gaziantep, Turkey
[2] Avukat Cengiz Gokcek State Hosp, Dept Dermatol, Gaziantep, Turkey
[3] Med Pk Hosp, Dermatol Clin, Tarsus, Turkey
关键词
Psoriasis; cyclosporine; acitretin; interleukin-2 (IL-2); tumour necrosis factor-alpha (TNF-alpha); ETRETINATE; THERAPY; MULTICENTER; ACTIVATION; TRIAL; SKIN;
D O I
10.1177/0300060514539280
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: A prospective, randomized clinical study to compare the short-term effects of cyclosporin and acitretin on psoriasis severity, and serum interleukin (IL)-2 and tumour necrosis factor (TNF)-alpha concentrations. Methods: Patients with moderate-to-severe plaque-type psoriasis were randomly assigned to receive either 3 mg/kg per day cyclosporine or 0.3-0.5 mg/kg per day acitretin for 8 weeks. Disease severity (psoriasis area severity index [PASI] score) and serum IL-2 and TNF-alpha concentrations were determined before and after treatment. Results: PASI scores and serum IL-2 and TNF-alpha concentrations were significantly decreased after treatment with either cyclosporine (n = 21) or acitretin (n = 25). There were no statistically significant between-group differences in any parameter. Conclusions: Acitretin and cyclosporine are equally effective in the treatment of moderate-to-severe plaque-type psoriasis.
引用
收藏
页码:1118 / 1122
页数:5
相关论文
共 27 条
[1]  
Af N, 2013, ACTA CLIN BELG, V68, P433
[2]   INTRALESIONAL T-LYMPHOCYTE ACTIVATION AS A MEDIATOR OF PSORIATIC EPIDERMAL HYPERPLASIA [J].
BATACSORGO, Z ;
HAMMERBERG, C ;
VOORHEES, JJ ;
COOPER, KD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 105 (01) :S89-S94
[3]   Acitretin revisited in the era of biologics [J].
Booij, Marielle Te ;
Van de Kerkhof, Peter C. M. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (02) :86-89
[4]   Psoriasis - epidemiology and clinical spectrum [J].
Christophers, E .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) :314-320
[5]   Effects of cyclosporin A on immune activation markers in patients with active psoriasis [J].
Economidou, J ;
Barkis, J ;
Demetriou, Z ;
Avgerinou, G ;
Psarra, K ;
Degiannis, D ;
Vareltzidis, A ;
Katsambas, A .
DERMATOLOGY, 1999, 199 (02) :144-148
[6]   CYCLOSPORINE FOR PLAQUE-TYPE PSORIASIS - RESULTS OF A MULTIDOSE, DOUBLE-BLIND TRIAL [J].
ELLIS, CN ;
FRADIN, MS ;
MESSANA, JM ;
BROWN, MD ;
SIEGEL, MT ;
HARTLEY, AH ;
ROCHER, LL ;
WHEELER, S ;
HAMILTON, TA ;
PARISH, TG ;
ELLISMADU, M ;
DUELL, E ;
ANNESLEY, TM ;
COOPER, KD ;
VOORHEES, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (05) :277-284
[7]   Cyclosporine in severe psoriasis: Results of a meta-analysis in 579 patients [J].
Faerber L. ;
Braeutigam M. ;
Weidinger G. ;
Mrowietz U. ;
Christophers E. ;
Schulze H.J. ;
Mahrle G. ;
Meffert H. ;
Drechsler S. .
American Journal of Clinical Dermatology, 2001, 2 (1) :41-47
[8]   CYCLOSPORINE VERSUS ETRETINATE - ITALIAN MULTICENTER COMPARATIVE TRIAL IN SEVERE PLAQUE-FORM PSORIASIS [J].
FINZI, AF ;
MOZZANICA, N ;
PIGATTO, PD ;
CATTANEO, A ;
IPPOLITO, F ;
CARDUCCI, M ;
SACERDOTE, G ;
CAVALIERI, R ;
PAPI, M ;
DIDONA, B ;
DEPITA, O ;
SANTOIANNI, P ;
BRUNETTI, B ;
DELFINO, M ;
MONTAGNANI, A ;
BARDAZZI, F ;
PELUSO, AM ;
TOSTI, A ;
CARLESIMO, OA ;
CLERICO, R ;
CARLESIMO, M ;
BOTTONI, U ;
INDELICATO, V ;
ANDREASSI, L ;
PEROTTI, R ;
GIANNOTTI, B ;
CARLI, P ;
PANCONESI, E ;
CAMPOLMI, P ;
BONAN, P ;
ZINA, G ;
BEDELLO, PG ;
DEPAOLI, M ;
SCARPA, C ;
KOKELJ, F ;
MINKUSCH, E ;
SIRCHIA, G ;
ANIASI, A ;
DELLACASAALBERIGHI, O ;
CORBETTA, G .
DERMATOLOGY, 1993, 187 :8-18
[9]   Psoriasis: a fresh took [J].
Galadari, I ;
Sharif, MO ;
Galadari, H .
CLINICS IN DERMATOLOGY, 2005, 23 (05) :491-502
[10]  
Geiger J M, 2003, Skin Therapy Lett, V8, P1